Sugi Predict

Sugi Predict / Compounds / SCHEMBL1767668

SCHEMBL1767668

SCHEMBL1767668

CC(=O)c1ccc(C(=O)N[C@@H](CCCCN)C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 9/20 0.55
▸ CA1 P00915 4/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ ERAP2 Q6P179 4/20 0.54
▸ LNPEP Q9UIQ6 4/20 0.54
▸ ERAP1 Q9NZ08 2/20 0.54
▸ HPGDS O60760 1/20 0.51
▸ FOLH1 Q04609 1/20 0.49
▸ CTSB P07858 1/20 0.48
▸ C3AR1 Q16581 1/20 0.48
▸ ITGB3 P05106 1/20 0.47
▸ ITGA2B P08514 1/20 0.47
▸ CASR P41180 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1767664 1.00 CA2 (0.55) CA2CA1CA12CA9ERAP2
SCHEMBL6815759 1.00 CA2 (0.55) CA2CA1CA12CA9ERAP2
Hydrochloric Acid SCHEMBL2327717 0.99 CA2 (0.54) CA2CA1CA12CA9ERAP2
SCHEMBL9716692 0.89 CA2 (0.55) CA2CA1CA12CA9ERAP2
SCHEMBL24518200 0.89 CA2 (0.55) CA2CA1CA12CA9ERAP2
SCHEMBL9716715 0.87 ERAP2 (0.55) CA2CA1CA12CA9ERAP2
SCHEMBL9716710 0.87 ERAP2 (0.55) CA2CA1CA12CA9ERAP2
SCHEMBL7034241 0.87 LNPEP (0.60) CA2CA1CA12CA9ERAP2
SCHEMBL7034236 0.87 LNPEP (0.60) CA2CA1CA12CA9ERAP2
SCHEMBL607885 0.87 ITGB3 (0.60) CA2CA1CA12CA9ERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118767115-A Growth hormone with prolonged in vivo efficacy 诺沃—诺迪斯克保健股份有限公司 2024-10-15 — — CN disclosed
CN-118767116-A Growth hormone with prolonged in vivo efficacy 诺沃—诺迪斯克保健股份有限公司 2024-10-15 — — CN disclosed
CN-118767117-A Growth hormone with prolonged in vivo efficacy 诺沃—诺迪斯克保健股份有限公司 2024-10-15 — — CN disclosed
CN-106139158-B Growth hormone with prolonged in vivo efficacy 诺沃—诺迪斯克保健股份有限公司 2024-06-21 — — CN disclosed
US-20200102568-A1 Growth Hormones with Prolonged In-Vivo Efficacy NOVO NORDISK HEALTHCARE AG (CH) 2020-04-02 — — US disclosed
EP-2525834-B1 GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY NOVO NORDISK HEALTHCARE AG (CH) 2019-07-17 — — EP disclosed
US-20190203213-A1 Growth Hormones with Prolonged In-Vivo Efficacy NOVO NORDISK HEALTHCARE AG (CH) 2019-07-04 — — US disclosed
US-20170239362-A1 Growth Hormones with Prolonged In-Vivo Efficacy NOVO NORDISK HEALTHCARE AG (CH) 2017-08-24 — — US disclosed
US-9695226-B2 Growth hormones with prolonged in-vivo efficacy NOVO NORDISK HEALTHCARE AG (CH) 2017-07-04 — — US disclosed
US-8865868-B2 Conjugated proteins with prolonged in vivo efficacy NOVO NORDISK HEALTHCARE AG (CH) 2014-10-21 — — US disclosed
US-8779109-B2 Growth hormones with prolonged in-vivo efficacy NOVO NORDISK HEALTH CARE AG (CH) 2014-07-15 — — US disclosed
US-20140107324-A1 Growth Hormones with Prolonged In-Vivo Efficacy NOVO NORDISK HEALTH CARE AG (CH) 2014-04-17 — — US disclosed
CN-102112157-B Conjugated proteins with prolonged in vivo efficacy NOVO NORDISK AS 2013-05-29 — — CN disclosed
US-20120309944-A1 Growth Hormones With Prolonged In-Vivo Efficacy NOVO NORDISK HEALTH CARE AG (CH) 2012-12-06 — — US disclosed
EP-2525834-A1 GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY Novo Nordisk Health Care AG (CH) 2012-11-28 — — EP disclosed
US-20110223151-A1 CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY NOVO NORDISK HEALTH CARE AG (CH) 2011-09-15 — — US disclosed
WO-2011089255-A1 GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY NOVO NORDISK HEALTH CARE AG (CH) 2011-07-28 — — WO disclosed
CN-102112157-A Conjugated proteins with prolonged in vivo efficacy NOVO NORDISK AS 2011-06-29 — — CN disclosed
EP-2323694-A1 CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY Novo Nordisk Health Care AG (CH) 2011-05-25 — — EP disclosed
WO-2010015668-A1 CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY NOVO NORDISK A/S (DK) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102568-A1 Growth Hormones with Prolonged In-Vivo Efficacy SHBG, GHRHR, GHITM CA2 4740/4885CA1 3769/4885CA12 3128/4885
US-20120309944-A1 Growth Hormones With Prolonged In-Vivo Efficacy GHRHR, SHBG, GHSR CA2 4691/4885CA1 3814/4885CA12 2840/4885
US-20170239362-A1 Growth Hormones with Prolonged In-Vivo Efficacy SHBG, GHRHR, GHITM CA2 4740/4885CA1 3769/4885CA12 3128/4885
US-20190203213-A1 Growth Hormones with Prolonged In-Vivo Efficacy SHBG, GHRHR, GHITM CA2 4740/4885CA1 3769/4885CA12 3128/4885
US-20140107324-A1 Growth Hormones with Prolonged In-Vivo Efficacy SHBG, GHRHR, GHITM CA2 4740/4885CA1 3769/4885CA12 3128/4885
US-20110223151-A1 CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY F13B, F13A1, F2 CA2 4295/4885CA1 3642/4885CA12 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.